DJIA 17,683.58 -46.53 -0.26%
NASDAQ 4,991.94 -17.27 -0.34%
S&P 500 2,068.76 -8.02 -0.39%
market minute promo

Amgen, Inc. (NASDAQ: AMGN)

company name or ticker
Company Photos
(Click to zoom)

Why AbbVie, Inc. Is a Better Long-Term Buy Than Gilead Sciences, Inc.

AbbVie and Gilead are often compared because of their competing hepatitis C drugs. These two biopharmas nevertheless have fundamentally different core areas of expertise and approaches to drug development. And these differences give AbbVie a better long-term outlook than Gilead.

Amgen Inc: Why You Shouldn't Count Chickens Before They Hatch

Amgen has shelved its once-promising psoriasis drug. Should investors worry?

Investing for Beginners: How to Start in Biotech

Biotech can be tricky to learn, so we asked the experts to give their best advice to beginners. Here is what they said.

'Fast Money' Recap: Bristol-Myers' Stock Is Ailing, Health Care on the Rise

Short Sellers Get Even More Ambitious Against Biotech Leaders

Recent Buy: Amgen

PRIMECAP Sells Portions of Its Top Two Stakes

Amgen And AstraZeneca's Deal On Psoriasis Drug Faces Termination

CNBC's Stock Pops & Drops From May 26

Amgen, AstraZeneca End Development Pact; Shares Sink